Jivika Bio Pharma

Thane West, Thane, Maharashtra

• It is an Antineoplastic agent and Monoclonal antibody. It binds to the Epidermal Growth Factor Receptor (EGFR) and aids in treating cancer.
• BIOMAb EGFR® targets the epidermal growth factor receptor (EGFR) present on the cell surface. The binding of certain growth factors to this receptor starts a series of events that are essential for cell growth, differentiation, and survival (both normal and cancerous). In cancerous cells there is an over expression of EGFR leading to uncontrolled cell growth, proliferation, survival and creation of new blood vessels. A very high level of EGFR is seen in many solid tumors and has been associated with poor treatment outcomes. BIOMAb EGFR® binds to the site on EGFR where the growth factors are supposed to bind and thus prevents cancer cells from proliferating, making new blood vessels and evading death. BIOMAb EGFR® also helps the body's immune system in recognizing the cancerous cells and fighting against them.
• Based on the experience of thousands of patients, BIOMAb EGFR® remains to be the unique monoclonal antibody of its class that has rarely exhibited any severe skin rashes till date.
• Studies conducted worldwide prove that BIOMAb EGFR® has a very good safety profile. In an Indian study of 92 patients with head and neck cancer, there have not been any incidences of severe skin rashes, hypomagnesaemia (low magnesium count) and other classical EGFR inhibition related side effects.
• The superior safety profile of BIOMAb EGFR® can be attributed to its proven unique molecular profile leading to its rapid clearance from normal cells, high tumor selectivity and specificity and its ability to enhance the antitumor effects of radiotherapy and chemotherapy.
• BIOMAb EGFR® has been seen to bind strongly to the tumor cells with high EGFR expression whereas in normal cells with low EGFR expression the binding is temporary or negligible. Unlike other EGFR inhibitors, there are negligible incidences of debilitating skin rashes, hypomagnesaemia or any other such side effects with BIOMAb EGFR® treatment.

Common Causes :

• Tobacco (including tobacco, sometimes called “chewing tobacco” or “snuff”) and alcohol are the most common risk factors of head & neck cancers, particularly those of the oral cavity, oropharynx, hypopharynx, and larynx.
• Eighty-five percent of head & neck cancers are linked to tobacco use. People who use both tobacco and alcohol are at a greater risk of developing these cancers than those who use either tobacco or alcohol.

Uses of Encicarb Injection : Encicarb Injection is used in the treatment of iron deficiency anemia and anemia due to chronic kidney disease.

Side effects of Encicarb Injection : Nausea, Flushing (sense of warmth in the face, ears, neck and trunk), Increased blood pressure, Dizziness, Decreased phosphate level in blood, Injection site reaction.

Side Effected :

• Mild burning/pain/bruising at the injection site
• hot flashes (flushing)
• increased sweating
• night sweats
• tiredness
• headache
• upset stomach
• breast changes
• acne
• joint/muscle aches
• trouble sleeping
• vaginal discomfort/dryness/bleeding
• swelling of the ankles/feet
• increased urination at night
• or dizziness may occur.

This prevents the cancerous cells from making cell division and therefore it inhibits the development of cancer.

Indication :

• This drug is indicated for breast Cancer, Lung Cancer, prostate cancer, stomach cancer, and head/neck cancer.
• Docenat 120 MG Injection is an anticancer agent which is used in the treatment of various cancers of lungs, head, stomach and breast.
• It should be used under the supervision of a qualified physician. Close monitoring of blood cell count and liver function test is necessary while receiving this medication